Science & Innovation

Explore the technology, evidence and quality principles behind Super Cells™.

Super Cells™ is a proprietary freeze-dried (lyophilised) exosome formulation. Product materials describe up to 55 billion exosome particles derived from source-cell harvests of up to 200 million Mesenchymal Stem Cells (MSCs), with preservation methods designed to maintain structural integrity.

The source tissue is voluntarily donated after birth and screened before processing. Source-cell selection, formulation and preservation are central to the product’s cellular-science approach.

The product materials describe three biotechnology patents supporting the Super Cells™ platform. Its stated points of differentiation include source-cell selection, exosome concentration and freeze-drying technology.

Patent protection and published clinical evidence serve different purposes. Patents concern intellectual property; research publications help assess biological mechanisms, clinical outcomes and the limits of the evidence for specific applications.

The manufacturing materials reference cGMP and cell-and-gene-therapy practices, ISO 14644 cleanroom standards, ISO 17025 laboratory standards, and U.S. FDA Human Cell & Tissue Establishment registration.

Ethical sourcing, donor screening, controlled processing and clinical oversight form the quality framework described for Super Cells™. Establishment registration and laboratory standards are distinct from regulatory approval of a product or a particular treatment.